

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM691965

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Trademark Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Biohaven Therapeutics Ltd		11/30/2021	business company limited by shares: VIRGIN ISLANDS, BRITISH
RECEIVING PARTY DATA			
Name:	Sixth Street Specialty Lending, Inc., as Administrative Agent		
Street Address:	888 Seventh Ave., 34th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10106		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	90788388	BIOHAVEN PHARMACEUTICALS	
CORRESPONDENCE DATA			
Fax Number:	2138918763		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	rhonda.deleon@lw.com		
Correspondent Name:	LATHAM & WATKINS LLP		
Address Line 1:	355 SOUTH GRAND AVENUE		
Address Line 4:	LOS ANGELES, CALIFORNIA 90071-1560		
ATTORNEY DOCKET NUMBER:	058423-0050		
NAME OF SUBMITTER:	Rhonda DeLeon		
SIGNATURE:	/Rhonda DeLeon/		
DATE SIGNED:	12/02/2021		
Total Attachments: 14			
source=Biohaven - Trademark Security Agreement Executed#page1.tif			
source=Biohaven - Trademark Security Agreement Executed#page2.tif			
source=Biohaven - Trademark Security Agreement Executed#page3.tif			
source=Biohaven - Trademark Security Agreement Executed#page4.tif			

OP \$40.00 90788388

source=Biohaven - Trademark Security Agreement Executed#page5.tif
source=Biohaven - Trademark Security Agreement Executed#page6.tif
source=Biohaven - Trademark Security Agreement Executed#page7.tif
source=Biohaven - Trademark Security Agreement Executed#page8.tif
source=Biohaven - Trademark Security Agreement Executed#page9.tif
source=Biohaven - Trademark Security Agreement Executed#page10.tif
source=Biohaven - Trademark Security Agreement Executed#page11.tif
source=Biohaven - Trademark Security Agreement Executed#page12.tif
source=Biohaven - Trademark Security Agreement Executed#page13.tif
source=Biohaven - Trademark Security Agreement Executed#page14.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT (this “**Agreement**”), dated as of November 30, 2021, is entered into by and among BioHaven Pharmaceutical Holding Company Ltd., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands with company number 1792178, Biohaven Pharmaceutical Ireland Designated Activity Company, a designated activity company incorporated under the laws of Ireland with registration number 666134 having a registered address at 6th Floor, South Bank House, Barrow Street, Dublin 4, D04 TR29, Ireland and Biohaven Therapeutics Ltd, a BVI business company limited by shares incorporated under the laws of the British Virgin Islands with company number 1916121 (each, a “**Grantor**” and, collectively, the “**Grantors**”) and Sixth Street Specialty Lending, Inc. (the “**Assignee**”), as Administrative Agent pursuant to (i) that certain Pledge and Security Agreement, dated as of August 7, 2020, among the Assignee, the Grantors and the other grantors party thereto (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”), and (ii) that certain Financing Agreement, dated as of August 7, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Financing Agreement**”), between, among others, certain of the Grantors’ affiliates, the Assignee, and certain Lenders party thereto.

Capitalized terms not otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as applicable.

WHEREAS, pursuant to the Security Agreement, each Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the federally registered Trademarks set forth on Schedule A hereto as of the date hereof.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors and the Assignee hereby agree as follows:

I. GRANT OF SECURITY INTEREST

A. Subject to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantors to the Assignee pursuant to the Security Agreement, each Grantor hereby grants to the Assignee a security interest in all of such Grantor’s right, title and interest in, to and under the Trademarks, whether now owned or existing or at any time hereafter acquired or arising and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of such Grantor’s Secured Obligations. For the purposes of this Agreement, “**Trademarks**” means (i) all United States and foreign trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos, Internet domain names and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, in the United States Patent and Trademark Office or in any similar office or agency of the United States or foreign country, and all common-law rights related thereto, including, without limitation, any of the foregoing referred to on Schedule A hereto, and (ii) the right to obtain all renewals thereof, provided that no Excluded Assets shall be included in the Trademarks.

B. Schedule A hereto contains a true and accurate list of all of Grantors’ registrations and applications for registration for the Trademarks in the United States and foreign countries (excluding Internet domain names) existing as of the date hereof.

C. The security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

II. MODIFICATIONS

This Agreement or any provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing Agreement. In connection with the foregoing, each Grantor authorizes the Assignee, upon notice to such Grantor, to modify this Agreement without obtaining such Grantor's signature to such modification, to the extent that such modification constitutes an amendment of Schedule A hereto, to add any right, title or interest in any Trademarks owned or subsequently acquired by such Grantor or to delete any reference to any right, title or interest in any Trademarks in which such Grantor no longer has or claims any right, title or interest. Each Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any Trademark to the security interests and perfection created or contemplated hereby or by the Security Agreement.

III. APPLICABLE LAW

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

IV. COUNTERPARTS; ELECTRONIC SIGNATURES

This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and all of said counterparts taken together shall be deemed to constitute one and the same instrument. For purposes of section 8(1) of the Electronic Transactions Act, 2001 of the British Virgin Islands, each party to this Agreement irrevocably consents to receiving the electronic signature of any other party to this Agreement that uses an electronic signature to execute this Agreement. For the purposes of this Section 15(1), "electronic signature" shall be construed so as to include the electronic signature of each witness, if any, of an electronic signature used to execute this Agreement. The words "execution," "execute," "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

SECTIONS 10.15 (CONSENT TO JURISDICTION) and 10.16 (WAIVER OF JURY TRIAL) OF THE FINANCING AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE, MUTATIS MUTANDIS.

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

ASSIGNEE:

SIXTH STREET SPECIALTY LENDING, INC.

By: _____


Name:  Jostina Easterly
Title: Chief Executive Officer

Address of Assignee:

888 Seventh Ave., 34th Floor
New York, NY 10106


GRANTORS:

**BIOHAVEN PHARMACEUTICAL HOLDING
COMPANY LTD.**

By: 
Name: Jim Engelhart
Title: Chief Financial Officer


Address of Grantor:
215 Church Street, New Haven, CT 06511

**BIOHAVEN PHARMACEUTICAL IRELAND
DESIGNATED ACTIVITY COMPANY**

By: 
Name: Clifford Bechtold
Title: President and General Manager, BPID

Address of Grantor:
51 South Richmond Street, Suite 101,
Dublin 2, Ireland, D02 FK02

BIOHAVEN THERAPEUTICS LTD

By: 
Name: Warren Volles
Title: Chief Legal Officer

Address of Grantor:
25 Science Park
150 Munson Ave.
New Haven, CT 06511

SCHEDULE A
TO TRADEMARK SECURITY AGREEMENT

Schedule A to TRADEMARK SECURITY AGREEMENT

Registered Trademarks

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Pharmaceutical Ireland Designated Activity Company	VYDURA	Australia	2151918	January 28, 2021	Registered
Biohaven Pharmaceutical Ireland Designated Activity Company	VYDURA	European Union	018384392	January 28, 2021	Registered
Biohaven Pharmaceutical Ireland Designated Activity Company	VYDURA	New Zealand	1169583	January 28, 2021	Registered
Biohaven Pharmaceutical Holding Company Ltd.	VYDURA	International Bureau (WIPO)	A0110924	July 8, 2021	Registered
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	China	1567616	November 18, 2020	Registered
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Colombia	SD20210000019	November 18, 2020	Registered
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	European Union	1567616	November 18, 2020	Registered
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	United Kingdom	1567616	November 18, 2020	Registered
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Monaco	1567616	November 18, 2020	Registered
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	International Bureau (WIPO)	A0102317	November 18, 2020	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Australia	2181976	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Brazil	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Canada	2109911	April 1, 2021	Registered

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Therapeutics Ltd	DAZLUMA	Switzerland	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	China	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Colombia	SD20210050353	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	United Kingdom	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Israel	339811	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	India	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Iceland	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Japan	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Republic of Korea	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Liechtenstein	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Monaco	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Mexico	M2555542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Norway	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	New Zealand	1179830	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Philippines	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Russian Federation	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Singapore	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Turkey	2021/078025	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	Ukraine	1593542	April 1, 2021	Registered
Biohaven Therapeutics Ltd	DAZLUMA	International Bureau (WIPO)	A0107178	April 1, 2021	Registered
Biohaven Pharmaceutical Holding Company Ltd.	MYHAVEN	Australia IPAU	2066984	January 7, 2020	Registered

Applications of Registration of Trademarks

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Pharmaceutical Holding Company Ltd.	VYDURA	Switzerland	1611747	July 8, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	VYDURA	United Kingdom	1611747	July 8, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	VYDURA	Iceland	1611747	July 8, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	VYDURA	Norway	1611747	July 8, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Australia	2200090	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Brazil	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Canada	2125313	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Switzerland	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Colombia	SD20210074116	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	European Union	1606180	June 22, 2021	Published
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	United Kingdom	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Hong Kong	305667175	June 24, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Israel	342241	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	India	5078060	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Iceland	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Japan	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Republic of Korea	1606180	June 22, 2021	Pending

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Liechtenstein	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Monaco	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Mexico	M2594542	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Norway	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	New Zealand	1185984	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Philippines	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Russian Federation	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Singapore	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Turkey	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Taiwan R.O.C.	110044158	June 23, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Ukraine	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	International Bureau (WIPO)	A0110259	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Australia	2147017	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Brazil	501567616	November 18, 2020	Published
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Canada	2074569	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Switzerland	1567616	November 18, 2020	Pending

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Hong Kong	305453758	November 19, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Israel	335016	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	India	4808796	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Iceland	1567616	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Japan	1567616	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Republic of Korea	1567616	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Mexico	M2479976	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Norway	1567616	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	New Zealand	1167791	November 18, 2020	Published
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Philippines	1567616	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Russian Federation	1567616	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Singapore	1567616	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Turkey	2021/070590	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	South Africa	202031759	November 17, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	South Africa	202031760	November 17, 2020	Pending
Biohaven Therapeutics Ltd	DAZLUMA	European Union	1593542	April 1, 2021	Published
Biohaven Therapeutics Ltd	DAZLUMA	Hong Kong	305583501	April 2, 2021	Pending
Biohaven Therapeutics Ltd	DAZLUMA	South Africa	202109839	April 6, 2021	Pending

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Australia		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Brazil		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Canada		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Switzerland		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	China		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Colombia		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	European Union		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	United Kingdom		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Hong Kong	305737122	September 3, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Israel		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	India		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Iceland		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Japan		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Liechtenstein		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Monaco		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Mexico		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Norway		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	New Zealand		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Philippines		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Russian Federation		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Singapore		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Turkey		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Taiwan R.O.C.	110063549	September 2, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	Ukraine		September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	International Bureau (WIPO)	A0113136	September 1, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN LABS	South Africa	202126995	September 2, 2021	Pending

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Therapeutics Ltd	BIOHAVEN LABS	South Africa	202126996	September 2, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Australia		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Brazil		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Canada		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Switzerland		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	China		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Colombia		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	European Union		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	United Kingdom		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Hong Kong	305745808	September 15, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Israel		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	India		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Iceland		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Japan		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Republic of Korea		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Liechtenstein		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Monaco		September 13, 2021	Pending

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Mexico		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Norway		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	New Zealand		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Philippines		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Russian Federation		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Singapore		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Turkey		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	Ukraine		September 13, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	TECSPIRET	International Bureau (WIPO)	A0113552	September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Australia		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Brazil		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Canada		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Switzerland		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	China		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Colombia		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	European Union		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	United Kingdom		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Hong Kong	305745790	September 15, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Israel		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	India		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Iceland		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Japan		September 13, 2021	Pending

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Therapeutics Ltd	VYGLXIA	Liechtenstein		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Monaco		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Mexico		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Norway		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	New Zealand		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Philippines		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Russian Federation		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Singapore		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Republic of Korea		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Turkey		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	Ukraine		September 13, 2021	Pending
Biohaven Therapeutics Ltd	VYGLXIA	International Bureau (WIPO)	A0113549	September 13, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVEN PHARMACEUTICALS LOGO	United States of America	90750254	June 22, 2021	Pending
Biohaven Therapeutics Ltd	BIOHAVENLABS LOGO	United States of America	90750254 (for classes 100, 101 only)	June 2, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	MYHAVEN	Canada CIPPO	2010329	January 7, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	VYDURA	WIPO (Madrid) ICH, GB, IS, NO	1611747	July 8, 2021	Pending

GRANTOR	TITLE	COUNTRY NAME	SERIAL NO.	FILING DATE	STATUS
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Australia IPAU	2200090	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Canada CIPO	2125313	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Colombia SIC	SD20210074116	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Israel ELS	342241	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	WIPO (Madrid) IAU, BR, CA, CH, CO, EU, GB, IL, IN, IS, JP, KR, LI, MC, MX, NO, NZ, PH, RU, SG, TR, UAE	1606180	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	Mexico IMPO	M2594542	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	New Zealand IPONZ	1185984	June 22, 2021	Pending
Biohaven Pharmaceutical Holding Company Ltd.	NEUROINNOVATION	Mexico IMPO	M2479977	November 18, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	MYHAVEN	Israel ELS	324859	January 7, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	MYHAVEN	Mexico IMPO	M2327196	January 7, 2020	Pending
Biohaven Pharmaceutical Holding Company Ltd.	BIOHAVEN	India IPI	5078060	June 22, 2021	Pending